RNAi therapeutic

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

Representative image of a leukemia drug development and biopharma acquisition theme, illustrating why Merck’s $6.7bn Terns Pharmaceuticals deal and TERN-701 are drawing attention as the Keytruda patent cliff approaches.

Merck’s $6.7bn Terns Pharmaceuticals buy puts CML drug TERN-701 in play as Keytruda patent cliff nears

Representative image of an Infosys office building, reflecting the firm’s global push to scale Topaz as a full-stack generative AI transformation platform.

Why is Infosys buying Stratus now as insurance platform modernization enters an AI-heavy phase?

Volex (AIM: VLX) upgrades FY2026 revenue to at least $1.22bn as AI data centre demand doubles and board eyes Main Market move

Boliden AB (STO: BOL) warns Garpenberg seismic damage will cut 2026 output and hit Q1 EBITDA

Alnylam, Dicerna form RNAi collaboration for alpha-1 liver disease

Alnylam Pharmaceuticals and Dicerna Pharmaceuticals are joining forces to develop and commercialize ribonucleicacid interference therapies (RNAi therapeutics) for…

bypharmanewsdaily

April 8, 2020

Alnylam Pharmaceuticals completes patient enrollment for Phase 3 trial of givosiran in acute hepatic porphyrias

Alnylam Pharmaceuticals has announced the completion of patient enrollment for its pivotal phase 3 trial, ENVISION, which evaluates…

bypharmanewsdaily

August 22, 2018

The Latest

Merck’s $6.7bn Terns Pharmaceuticals buy puts CML drug TERN-701 in play as Keytruda patent cliff nears

Why is Infosys buying Stratus now as insurance platform modernization enters an AI-heavy phase?

Volex (AIM: VLX) upgrades FY2026 revenue to at least $1.22bn as AI data centre demand doubles and board eyes Main Market move

Boliden AB (STO: BOL) warns Garpenberg seismic damage will cut 2026 output and hit Q1 EBITDA

Alnylam, Dicerna form RNAi collaboration for alpha-1 liver disease

Alnylam Pharmaceuticals completes patient enrollment for Phase 3 trial of givosiran in acute hepatic porphyrias

Merck’s $6.7bn Terns Pharmaceuticals buy puts CML drug TERN-701 in play as Keytruda patent cliff nears

Why is Infosys buying Stratus now as insurance platform modernization enters an AI-heavy phase?

Volex (AIM: VLX) upgrades FY2026 revenue to at least $1.22bn as AI data centre demand doubles and board eyes Main Market move

Boliden AB (STO: BOL) warns Garpenberg seismic damage will cut 2026 output and hit Q1 EBITDA

Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?

HICL Infrastructure (LSE: HICL) to sell A63 Motorway stake for £311m at 21% premium to book value

Could repeated VCN-01 dosing overcome long-standing survival barriers in metastatic PDAC?

Atossa Therapeutics (NASDAQ: ATOS) deepens Z-endoxifen bet as 2025 losses widen and rare disease optionality grows